Fortress Biotech, Inc. (FBIO)

Fortress Biotech, Inc. (FBIO) Healthcare & Pipeline Overview

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products, focusing on dermatology and late-stage product candidates. With a diverse pipeline and a market capitalization of $99.49M, the company aims to address unmet medical needs through strategic collaborations and internal development programs in a competitive healthcare landscape.

What Is the Investment Thesis for FBIO?

Fortress Biotech presents a mixed investment thesis. The company's diverse pipeline of dermatology products and late-stage clinical candidates offers potential growth opportunities. The company's gross margin stands at 66.9%, indicating strong pricing power in its marketed products. However, the company's success hinges on the clinical trial outcomes and regulatory approvals of its late-stage candidates, which are subject to inherent risks. The company's collaboration-focused model could drive innovation and expansion. Investors should closely monitor clinical trial data, regulatory milestones, and market uptake of approved products to assess the company's long-term value.

Based on FMP financials and quantitative analysis

FBIO Key Highlights

• Market Cap of $99.49M reflects the company's valuation in the biopharmaceutical sector.
• P/E ratio of 0.7 suggests the company is potentially undervalued compared to its earnings.
• Profit Margin of 10.8% indicates the company's ability to generate profit from its revenue.
• Gross Margin of 66.9% demonstrates strong pricing power and efficient cost management in its product sales.
• Beta of 1.45 suggests the stock is more volatile than the market, potentially offering higher risk and reward.

Who Are FBIO's Competitors?

FBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FBIO's Key Strengths?

• Diverse product pipeline across multiple therapeutic areas.
• Established dermatology product portfolio with recurring revenue.
• Collaboration-focused business model leveraging external expertise.
• Focus on high-value niche markets like rare diseases.

What Are FBIO's Weaknesses?

• Reliance on clinical trial outcomes and regulatory approvals.
• Limited financial resources compared to larger pharmaceutical companies.
• High R&D expenses and long development timelines.
• Dependence on partnerships for commercialization.

What Could Drive FBIO Stock Higher?

• Clinical trial results for Cosibelimab in metastatic cancers.
• Regulatory submission for CUTX-101 for Menkes disease.
• Commercialization efforts for existing dermatology product portfolio.
• Advancement of early-stage product candidates through preclinical development.

What Are the Key Risks for FBIO?

• Financial-distress signal — its Altman Z-Score of 0.10 sits in the distress zone (elevated bankruptcy risk).
• Unfavorable clinical trial results for late-stage candidates.
• Regulatory delays or rejection of product approvals.
• Competition from established pharmaceutical companies.
• Patent expirations and generic erosion of key products.
• Dependence on collaborations for funding and development.

What Are the Growth Opportunities for FBIO?

• Expansion of Dermatology Product Portfolio: Fortress Biotech can capitalize on the growing dermatology market by introducing new and improved products for various skin conditions. The global dermatology market is projected to reach $36.6 billion by 2026, offering significant growth potential. By focusing on innovative formulations and targeted therapies, Fortress Biotech can expand its market share and drive revenue growth. The timeline for new product launches typically ranges from 1-3 years, depending on regulatory approvals and clinical trial requirements.
• Advancement of Late-Stage Oncology Candidates: The company's late-stage oncology candidates, such as Cosibelimab and CK-101, represent significant growth opportunities in the expanding oncology market. The global oncology market is expected to reach $286.6 billion by 2030. Positive clinical trial results and regulatory approvals could lead to substantial revenue streams. The timeline for potential approvals and commercialization is estimated to be within the next 2-4 years.
• Development of Treatments for Rare Diseases: Fortress Biotech's focus on rare diseases, such as Menkes disease with CUTX-101, provides a unique growth avenue. The rare disease market is characterized by high unmet needs and limited competition. Successful development and commercialization of treatments for rare diseases can result in premium pricing and long-term revenue streams. The timeline for rare disease drug development can vary, but typically ranges from 3-5 years.
• Strategic Collaborations and Partnerships: Fortress Biotech's collaboration-focused model allows it to leverage external expertise and resources to accelerate drug development and expand its product pipeline. Strategic partnerships with universities, research institutes, and pharmaceutical companies can provide access to innovative technologies and funding opportunities. These collaborations can lead to the development of new products and the expansion of the company's market reach. The impact of these collaborations can be seen within 1-2 years through the advancement of clinical programs.
• Expansion into Gene Therapy: Fortress Biotech's preclinical product candidates, including AAV-ATP7A gene therapy and AVTS-001 gene therapy, represent a long-term growth opportunity in the rapidly evolving gene therapy market. The gene therapy market is projected to reach $13.8 billion by 2024. Successful development and commercialization of gene therapies can provide transformative treatments for genetic diseases. The timeline for gene therapy development is typically longer, ranging from 5-7 years, due to the complexity of the technology and regulatory requirements.

What Opportunities Does FBIO Have?

• Expansion of dermatology product line through new formulations.
• Advancement of late-stage oncology candidates to market.
• Strategic acquisitions of complementary technologies or products.
• Geographic expansion into emerging markets.

What Threats Does FBIO Face?

• Competition from established pharmaceutical companies.
• Patent expirations and generic erosion of key products.
• Unfavorable clinical trial results or regulatory setbacks.
• Changes in healthcare regulations and reimbursement policies.

What Are FBIO's Competitive Advantages?

• Proprietary formulations and patents for dermatology products.
• Clinical data and regulatory exclusivity for late-stage product candidates.
• Strategic collaborations with leading research institutions.
• Focus on niche markets with high unmet medical needs.

What Does FBIO Do?

Fortress Biotech, Inc., established in 2006 and formerly known as Coronado Biosciences, Inc., is a biopharmaceutical company dedicated to developing and commercializing pharmaceutical and biotechnology products. Headquartered in Bay Harbor Islands, New York, the company has evolved into a multifaceted entity with a focus on dermatology and the development of late-stage product candidates across various therapeutic areas. Fortress Biotech markets a range of dermatology products, including Ximino capsules for acne, Targadox for severe acne, Exelderm cream for ringworm and jock itch, Ceracade for dry skin, Luxamend for wound management, and Accutane capsules for severe nodular acne. Beyond dermatology, the company is advancing a pipeline of late-stage product candidates, such as intravenous Tramadol for post-operative pain, CUTX-101 for Menkes disease, MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for EGFR mutation-positive NSCLC, CAEL-101 for amyloid light chain amyloidosis, a Triplex vaccine for cytomegalovirus, and CEVA101 for traumatic brain injury. Fortress Biotech also has early-stage and preclinical product candidates, including MB-102 for blastic plasmacytoid dendritic cell neoplasm and AAV-ATP7A gene therapy. The company actively collaborates with universities, research institutes, and pharmaceutical companies to expand its research and development efforts.

What Products and Services Does FBIO Offer?

• Develops and commercializes pharmaceutical products.
• Focuses on dermatology products for conditions like acne and skin infections.
• Advances late-stage product candidates for post-operative pain and genetic disorders.
• Develops treatments for various cancers, including metastatic cancers and non-small cell lung cancer.
• Works on therapies for rare diseases like Menkes disease and X-linked severe combined immunodeficiency.
• Engages in early-stage research for conditions like glioblastoma and multiple myeloma.
• Collaborates with universities and research institutes to expand its pipeline.

How Does FBIO Make Money?

• Develops and acquires pharmaceutical product candidates.
• Markets and sells dermatology products directly.
• Out-licenses or partners for the commercialization of certain products.
• Collaborates with other companies and research institutions to advance its pipeline.

What Industry Does FBIO Operate In?

Fortress Biotech operates in the competitive biotechnology industry, characterized by rapid innovation and high regulatory hurdles. The market for dermatology products is driven by increasing awareness of skin conditions and the availability of advanced treatments. The oncology market, where Fortress Biotech has several candidates, is experiencing significant growth due to the rising incidence of cancer and advancements in immunotherapy. The company's success depends on its ability to navigate the complex regulatory landscape, secure partnerships, and differentiate its products in a crowded market.

Who Are FBIO's Key Customers?

• Patients with dermatological conditions like acne and skin infections.
• Hospitals and clinics using post-operative pain management solutions.
• Patients with rare genetic disorders seeking specialized treatments.
• Oncology patients requiring advanced cancer therapies.

Company Profile

Fortress Biotech, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bay Harbor Islands, US. The company is led by CEO Lindsay Allan Rosenwald. FBIO has traded publicly since 2011.

How Fortress Biotech, Inc. Is Valued

Fortress Biotech, Inc. carries a market capitalization of $99.49M, placing it in the micro-cap category. Relative to its peer group, FBIO's quantitative score of 41/100 is below the peer average of 76/100.

ROE 164%Key Financial Metrics

Return on equity for Fortress Biotech, Inc. stands at 163.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 35.8%, showing how much profit it generates from its asset base. FBIO trades at a trailing price-to-earnings ratio of 0.72, below the Healthcare sector average of ~23x. A current ratio of 2.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 131.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Fortress Biotech, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.10 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Fortress Biotech, Inc. revenue of about $79.9M for fiscal 2026, with EPS near $2.40.

Net buyingInsider Activity

Over the past six months, Fortress Biotech, Inc. insiders filed 3 SEC Form 4 transactions — 0 sales and 3 purchases. On net that is roughly 954K shares acquired (about $6K) — insiders putting money in tends to read as conviction.

FBIO Financials

FBIO Latest News

FBIO Analyst Consensus

FBIO MoonshotScore

Common Questions About FBIO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources